Skip to content

IMDX IMDX Restricted Cash

Restricted Cash at other companies

CareDx logo
CareDxCDNA
$551K+0.2%
Guardant Health logo
Guardant HealthGH
$112.15M+6.5%
GeneDx Holdings logo
GeneDx HoldingsWGS
$992K+0.2%
Veracyte logo
VeracyteVCYT
$1.66M+0.7%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Agilent Technologies logo
Agilent TechnologiesA

Other financials

Income statement

See full
Revenue$32.0K-98.5%
Gross profit$15.0K-98.9%
Operating income-$4.4M+35.1%
Net income-$4.3M+35.7%
EPS (diluted)-$0.12+53.8%

Balance sheet

See full
Cash & equivalents$28.2M-9.1%
Total debt$2.9M-13.5%
Total equity-$10.7M-205%
Total assets$40.4M-33.0%

Cash flow

See full
Operating cash flow-$7.6M-30.8%
CapEx$613.0K+99.7%
Free cash flow-$8.3M-34.3%

Valuation

See full
Market cap$185.35M+92.3%
Enterprise value$160.03M+113%
P/S95.1×+72.5×

Profitability

See full
Gross margin51.3%-3.0pp
Operating margin-2,500.7%+4,459pp
Net margin-2,454.6%+4,017pp
FCF margin-1,409.7%-6,023pp

Returns & leverage

See full
Return on equity-532.9%-717pp
Debt / equity2.9×+2.8×
Current ratio2.5×-1.2×

Where this comes from

Reported directly by IMDX in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.

The official record: IMDX’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about IMDX's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IMDX's restricted cash?
IMDX (IMDX) reported restricted cash of $729K in Q1 2026.
How has IMDX's restricted cash changed year-over-year?
IMDX's restricted cash decreased by 57.1% year-over-year, from $1.7M to $729K.
What is the long-term trend for IMDX's restricted cash?
Over 5 years (2020 to 2025), IMDX's restricted cash has grown at a -15.6% compound annual growth rate (CAGR), from $1.7M to $729K.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.